NIH / NCATS SBIR & STTR — AI Drug Discovery

NIH / National Center for Advancing Translational Sciences

HIGH T4 Startup

Strategy Notes

AI/ML drug discovery is an explicit NCATS priority area. Phase I ~$270K, Phase II ~$2M. Investigate international applicant eligibility — some mechanisms allow non-US entities with US collaboration. Strong strategic fit for resistance prediction.

Key Materials

NIH application (Specific Aims + Research Strategy + Budget), US entity or collaboration agreement, PI biosketch

Gate / Eligibility

US entity or US collaborator typically required at Phase I. Check NCATS international applicant policy. May need US co-PI or subsidiary.

Your Notes

Status & Deadline

Status: INELIGIBLE
Deadline: Rolling (multiple receipt dates)
Cycle: Rolling
Amount: Phase I ~$270,000 · Phase II ~$2,000,000
Type: Grant
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-09 OPEN → INELIGIBLE · NIH SBIR/STTR requires the applicant to be a US-based small business concern (SBC) — organized for profit in the United States, with a principal place of business in the US, and at least 51% owned and controlled by US citizens or permanent resident aliens. Eniola is not incorporated, is domiciled in Lagos and planning EU relocation, and holds no US citizenship or permanent residency — all three are independent hard blockers with no waiver mechanism.